Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Primary results from the phase 3 MARIPOSA-2 study
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Primary results from the phase 3 MARIPOSA-2 study
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-10-23
DOI
10.1016/j.annonc.2023.10.117
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- (2023) L.E. Hendriks et al. ANNALS OF ONCOLOGY
- Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: Analysis of tissue IHC and ctDNA NGS.
- (2023) Benjamin Besse et al. JOURNAL OF CLINICAL ONCOLOGY
- Continuation of Third-Generation Tyrosine Kinase Inhibitors in Second-Line Trials for EGFR-Mutated Non–Small-Cell Lung Cancer: Regulatory Considerations
- (2023) Bernardo H.L. Goulart et al. JOURNAL OF CLINICAL ONCOLOGY
- Tissue and plasma-based mechanisms of resistance to first-line osimertinib in EGFR-mutant NSCLC: A multi-institutional cohort.
- (2023) Zofia Piotrowska et al. JOURNAL OF CLINICAL ONCOLOGY
- Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib.
- (2023) Helena Alexandra Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.
- (2023) James Chih-Hsin Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
- (2023) Byoung Chul Cho et al. NATURE MEDICINE
- ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer
- (2022) A. Passaro et al. ANNALS OF ONCOLOGY
- Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
- (2022) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- A phase II study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced non–small cell lung cancer: The OPAL study (NEJ032C/LOGIK1801).
- (2022) Atsushi Nakamura et al. JOURNAL OF CLINICAL ONCOLOGY
- Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2.
- (2022) Catherine A. Shu et al. JOURNAL OF CLINICAL ONCOLOGY
- Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.
- (2022) Matthew Krebs et al. JOURNAL OF CLINICAL ONCOLOGY
- EP08.02-003 Aumolertinib Plus Chemotherapy as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation andctDNA Cleared Analysis
- (2022) Y. Li et al. Journal of Thoracic Oncology
- MA07.04 Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy in Relapsed/Refractory EGFR-mutant NSCLC
- (2022) M.E. Marmarelis et al. Journal of Thoracic Oncology
- LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722
- (2022) T.S.K. Mok et al. ANNALS OF ONCOLOGY
- Osimertinib versus osimertinib plus chemotherapy for non–small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial
- (2021) Kentaro Tanaka et al. EUROPEAN JOURNAL OF CANCER
- 1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study
- (2021) N.B. Leighl et al. ANNALS OF ONCOLOGY
- P50.04 Amivantamab in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
- (2021) M. Nagasaka et al. Journal of Thoracic Oncology
- Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
- (2020) Adam J Schoenfeld et al. CLINICAL CANCER RESEARCH
- Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-cMet Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC
- (2020) Jiyeon Yun et al. Cancer Discovery
- Amivantamab (JNJ-61186372), An Fc Enhanced EGFR/cMet Bispecific Antibody Induces Receptor Downmodulation And Anti-tumor Activity By Monocyte/Macrophage Trogocytosis
- (2020) Smruthi Vijayaraghavan et al. MOLECULAR CANCER THERAPEUTICS
- YH25448, an irreversible EGFR-TKI with Potent Intracranial Activity in EGFR mutant non-small-cell lung cancer
- (2019) Jiyeon Yun et al. CLINICAL CANCER RESEARCH
- A Retrospective Study on Efficacy and Safety of Rivaroxaban and Dalteparin for Long-Term Treatment of Venous Thromboembolism in Patients with Lung Cancer
- (2019) Jang Ho Lee et al. RESPIRATION
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- (2019) Suresh S. Ramalingam et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study
- (2019) Myung-Ju Ahn et al. LANCET ONCOLOGY
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
- (2018) Geoffrey R. Oxnard et al. JAMA Oncology
- LBA51Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
- (2018) V A Papadimitrakopoulou et al. ANNALS OF ONCOLOGY
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors
- (2016) Sheri L. Moores et al. CANCER RESEARCH
- Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
- (2015) Jean-Charles Soria et al. LANCET ONCOLOGY
- Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants: a systematic review and meta-analysis
- (2013) Jing Zhang et al. THORAX
- Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
- (2009) A F Gazdar ONCOGENE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now